Shares of GlaxoSmithKline plc (LON:GSK) have earned an average recommendation of “Hold” from the twenty-six analysts that are covering the firm. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 1,668.38 ($20.65).

GSK has been the topic of a number of research analyst reports. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. Deutsche Bank AG reiterated a “hold” rating and set a GBX 1,700 ($21.04) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 28th. Jefferies Group upgraded GlaxoSmithKline plc to a “buy” rating and lifted their price target for the company from GBX 1,650 ($20.42) to GBX 2,000 ($24.75) in a report on Thursday, July 14th. BNP Paribas reiterated a “neutral” rating and set a GBX 1,430 ($17.70) price target on shares of GlaxoSmithKline plc in a report on Sunday, July 3rd. Finally, Independent Research GmbH set a GBX 1,800 ($22.28) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a report on Thursday, August 4th.

In related news, insider Slaoui,Moncef bought 28 shares of the company’s stock in a transaction dated Friday, August 12th. The stock was acquired at an average cost of GBX 2,208 ($27.33) per share, with a total value of £618.24 ($765.15). Also, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.95), for a total value of £169,300 ($209,529.70).

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

GlaxoSmithKline plc (LON:GSK) traded down 0.20% during midday trading on Tuesday, reaching GBX 1719.00. The company’s stock had a trading volume of 7,510,673 shares. The stock has a 50 day moving average of GBX 1,645.83 and a 200 day moving average of GBX 1,556.82. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,745.56. The firm’s market capitalization is GBX 83.56 billion.

The company also recently declared a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be issued a GBX 19 ($0.24) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.